Anti-DLG3 antibody produced in rabbit

Description

• Immunogen: Discs large homolog 3 recombinant protein epitope signature tag (PrEST)
• Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
• Biochem/physiol Actions: In human DLG3 (disks large homolog 3) encodes for synapse-associated protein 102 (SAP102) that belongs to the guanylate kinase protein family. It is found to be expressed during early brain development and is present to the postsynaptic density of excitatory synapses. Structurally, it is composed of three amino-terminal PDZ (PSD95, Dlg1, zo-1) domains, an Src homology domain, and a carboxyl-terminal guanylate kinase domain. The PDZ domains participates in mediating protein-protein interactions and also helps in binding to the short amino acid motifs at the carboxyl termini of interacting proteins. It plays a positive role in clustering of NMDA (N-methyl-D-aspartate) receptors at excitatory synapses as well as it negatively regulate cell proliferation through interaction with the C-terminal region of the polyposis coli tumor suppressor protein. Mutation in DLG3 gene causes a heterogeneous disorder: nonsyndromic X-linked mental retardation.
• Features and Benefits: Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways:IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.Protein array of 364 human recombinant protein fragments.
• Linkage: Corresponding Antigen APREST74014
• Physical form: Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
• Legal Information: Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany